Literature DB >> 18625819

Effects and treatment of inflammatory bowel disease during pregnancy.

Harvinder Brar, Adrienne Einarson.   

Abstract

QUESTION: I have several patients with inflammatory bowel disease (IBD) who are pregnant or planning pregnancies. What information can I give them regarding the possible effects of IBD on pregnancy and the medications used to treat IBD during pregnancy? ANSWER: Women with IBD appear to be at increased risk of giving birth prematurely, having low-birth-weight infants, and having cesarean sections. Neither 5-aminosalicylic acid nor sulfasalazine has been found to increase the rate of major malformations, fetal mortality, or morbidity. There is conflicting evidence regarding the use of corticosteroids and azathioprine and 6-mercaptopurine. There are limited data on the use of infliximab during pregnancy, although no pattern of defects or complications has been reported to date.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625819      PMCID: PMC2464785     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  20 in total

1.  Folic acid antagonists during pregnancy and the risk of birth defects.

Authors:  S Hernández-Díaz; M M Werler; A M Walker; A A Mitchell
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Possible embryotoxicity of sulfasalazine.

Authors:  A Craxi; F Pagliarello
Journal:  Arch Intern Med       Date:  1980-12

4.  Placental and mammary transfer of sulphasalazine.

Authors:  A K Khan; S C Truelove
Journal:  Br Med J       Date:  1979-12-15

5.  Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study.

Authors:  Bente Nørgård; Lars Pedersen; Lisbet A Christensen; Henrik T Sørensen
Journal:  Am J Gastroenterol       Date:  2007-04-16       Impact factor: 10.864

6.  Population-based case control study of the safety of sulfasalazine use during pregnancy.

Authors:  B Nørgård; A E Czeizel; M Rockenbauer; J Olsen; H T Sørensen
Journal:  Aliment Pharmacol Ther       Date:  2001-04       Impact factor: 8.171

7.  Possible teratogenicity of sulphasalazine.

Authors:  N M Newman; J F Correy
Journal:  Med J Aust       Date:  1983-05-28       Impact factor: 7.738

8.  The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study.

Authors:  Andrew Francella; Alan Dyan; Carol Bodian; Peter Rubin; Mark Chapman; Daniel H Present
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

9.  Ulcerative colitis and pregnancy.

Authors:  C P Willoughby; S C Truelove
Journal:  Gut       Date:  1980-06       Impact factor: 23.059

10.  Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.

Authors:  M Mogadam; W O Dobbins; B I Korelitz; S W Ahmed
Journal:  Gastroenterology       Date:  1981-01       Impact factor: 22.682

View more
  1 in total

1.  Inhibition of choriodecidual cytokine production and inflammatory gene expression by selective I-kappaB kinase (IKK) inhibitors.

Authors:  D De Silva; M D Mitchell; J A Keelan
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.